Status:
UNKNOWN
Changes of Left Atrial Function and Quality of Life in Patients With Left Atrial Appendage Occlusion
Lead Sponsor:
Ruiqin xie
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
A total of 105 patients with atrial fibrillation (AF) are scheduled to receive surgical treatment and will be divided into three groups. Left atrial appendage occlusion (LAAC), three-dimensional mappi...
Detailed Description
A total of 105 patients with atrial fibrillation (AF) are scheduled to receive surgical treatment and will be divided into three groups. Left atrial appendage occlusion (LAAC), three-dimensional mappi...
Eligibility Criteria
Inclusion
- Patients with AF lasting for more than one year;
- Antiarrhythmic drugs are ineffective;
- Age of patients is less than 80 years old;
- Cha2ds2-vasc score ≥ 2;
- Not suitable for long-term oral anticoagulants.
Exclusion
- Patients with a history of atrial thrombosis or valvular heart disease (moderate or severe valve stenosis or severe valve regurgitation);
- Patients undergoing prosthetic heart valve replacement;
- Pregnant women;
- Patients with previous liver and kidney diseases, malignant tumors or blood system diseases.
Key Trial Info
Start Date :
February 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 28 2022
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT04403412
Start Date
February 1 2020
End Date
April 28 2022
Last Update
September 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China, 050000